Increased deaths from fungal infections during the COVID-19 pandemic — National Vital Statistics System, United States, January 2020–December 2021

Jeremy A. W. Gold,1 Farida B. Ahmad,2 Jodi A. Cisewski,2 Lauren M. Rossen,2 Alejandro J. Montero,1 Kaitlin Benedict,1 Brendan R. Jackson,1 Mitsuru Toda1

1Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
2National Center for Health Statistics, Hyattsville, Maryland, USA

Corresponding author: Jeremy A. W. Gold, MD, MS, Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Mailstop H24-10, Atlanta, GA 30329, USA, jgold@cdc.gov

Running title: COVID-19–associated fungal deaths
ABSTRACT:

Background: COVID-19–associated fungal infections cause severe illness, but comprehensive data on disease burden are lacking. We analyzed US National Vital Statistics System (NVSS) data to characterize disease burden, temporal trends, and demographic characteristics of persons dying from fungal infections during the COVID-19 pandemic.

Methods: Using NVSS’s January 2018–December 2021 Multiple Cause of Death Database, we examined numbers and age-adjusted rates (per 100,000 population) of fungal deaths by fungal pathogen, COVID-19 association, demographic characteristics, and year.

Results: Numbers and age-adjusted rates of fungal deaths increased from 2019 (n = 4,833, rate 1.2, 95% confidence interval [CI] = 1.2–1.3) to 2021 (n = 7,199, rate 1.8, 95% CI = 1.8–1.8); of 13,121 fungal deaths during 2020–2021, 2,868 (21.9%) were COVID-19–associated. Compared with non-COVID-19–associated fungal deaths (n = 10,253), COVID-19–associated fungal deaths more frequently involved Candida (n = 776 [27.1%] versus n = 2,432 [23.7%]) and Aspergillus (n = 668 [23.3%] versus n = 1,486 [14.5%]) and less frequently involved other specific fungal pathogens. Fungal death rates were generally highest in non-White and non-Asian populations. Death rates from Aspergillus infections were approximately two times higher in the Pacific US census division compared with most other divisions.

Conclusions: Fungal deaths increased during 2020–2021 compared with previous years, primarily driven by COVID-19–associated fungal deaths, particularly those involving Aspergillus and Candida. Our findings may inform efforts to prevent, identify, and treat severe fungal infections in COVID-19 patients, especially in certain racial/ethnic groups and geographic areas.

Key words: death certificates; invasive fungal infections; COVID-19; aspergillosis; candidiasis
BACKGROUND

Fungal infections cost the US healthcare system >$7.2 billion each year and cause substantial morbidity and mortality [1, 2]. The most common pathogenic fungi include certain yeasts (e.g., Candida, Cryptococcus), yeast-like fungi (Pneumocystis), molds (e.g., Aspergillus, Mucorales spp.), and dimorphic fungi (e.g., Histoplasma, Coccidioides). The clinical spectrum of fungal diseases ranges from superficial mucocutaneous lesions to severe, life-threatening infections. Severe fungal infections typically affect persons with immunocompromising conditions such as solid organ and stem cell transplantation, cancer, receipt of immunosuppressive medications, advanced HIV disease, and critical illness [3-6]. Other increasingly recognized risk factors include uncontrolled diabetes, chronic lower respiratory tract diseases, influenza, and more recently, COVID-19 [2, 6].

Since the first US case was detected during January 2020 [7], more than 880,000 US residents have died from COVID-19 (as of March 9, 2022) [8]. COVID-19 might increase the risk for severe fungal infections because of COVID-19–related immune system dysfunction, structural lung damage, and treatments (e.g., corticosteroids, immunomodulatory drugs) that impair host defenses against fungal pathogens [6]. The development of severe fungal infections in COVID-19 patients can lead to poor outcomes, including death [6, 9-13].

In the United States, public health surveillance for most types of fungal infections is lacking. Data on the landscape of fungal infections during the COVID-19 pandemic era could help guide the prioritization of public health resources related to disease prevention, diagnosis, and treatment. Vital statistics data, made publicly available through the US National Vital Statistics System (NVSS), can provide comprehensive assessments of mortality burden and disease trends during public health emergencies [14]. We analyzed NVSS data to characterize fungal disease burden, temporal trends, and demographic characteristics of persons who died from fungal infections during January 2020–December 2021.
METHODS

We analyzed NVSS’s Provisional Multiple Cause of Death datafiles. These files include final mortality data for residents of the 50 US states and the District of Columbia during 2018–2020 and provisional mortality data for 2021. We accessed data on February 17, 2022, using CDC’s Wide-ranging Online Data for Epidemiologic Research (CDC-WONDER) (https://wonder.cdc.gov/mcd-icd10-provisional.html), a free, web-based platform. NVSS last updated the data analyzed for this report on February 6, 2022. The mortality data are based on death certificates, which are completed according to instructions provided by the National Center for Health Statistics [15]. Death certificates include a single underlying cause of death, up to 20 additional multiple causes of death, and demographic data. Causes of death are coded according to the International Classification of Diseases, Tenth Revision (ICD-10) [15]. We identified deaths involving fungal pathogens (“fungal deaths”) using the following ICD-10 codes: B44 (Aspergillus); B37 (Candida); B38 (Coccidioides); B45 (Cryptococcus); B39 (Histoplasma); B46 (Mucorales spp.); B59 (Pneumocystis); B35–B36, B40–B43, or B47–B48 (other specified fungal pathogens); and unspecified fungal pathogens (B49). We used ICD-10 code U07.1 to identify deaths involving COVID-19 (“COVID-19 deaths”). The underlying cause of death is the condition that started the chain of events leading to a person’s death. All diagnoses listed on a death certificate must be part of the causal pathway of events and conditions leading to death or be a significant condition that contributed to the death [15]; therefore, we defined death from a particular condition as the condition’s inclusion on the death certificate, regardless of whether the condition was a contributing or underlying cause.

We calculated age-adjusted death rates using the year 2000 standard US population [16]. For fungal deaths occurring during January 2018–December 2021, we examined the numbers, percentages, and age-adjusted rates by fungal pathogen, COVID-19 association (i.e., whether COVID-19 contributed to death [2020–2021 only]), and year. To visualize trends in fungal deaths during the COVID-19
pandemic, we examined the monthly number of fungal deaths by COVID-19 association alongside the monthly total number of COVID-19 deaths.

For fungal deaths occurring during January 2020–December 2021, we stratified data by COVID-19 association and examined numbers, percentages, and age-adjusted rates of death by sex, race/ethnicity, US census division of residence (https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html), and type of fungal disease; we examined crude death rates across 10-year age groups and urban-rural 2013 classifications of residence (https://www.cdc.gov/nchs/data_access/urban_rural.htm). Crude death rates were shown for urban-rural classification because age-stratified death rates by urban-rural status were not available on CDC-WONDER. Death rates based on counts of less than twenty were not calculated. We categorized race/ethnicity as Hispanic or Latino (Hispanic), non-Hispanic White (White), non-Hispanic Black (Black), non-Hispanic Asian (Asian), non-Hispanic American Indian or Alaska Native (AI/AN), non-Hispanic Native Hawaiian or other Pacific Islander (NHPI), non-Hispanic multiracial, and unknown. We analyzed data using the six single race categories because these were the only categories for which race-specific population estimates for rate denominators were available on the CDC-WONDER platform.

RESULTS

During 2018–2021, 22,700 fungal deaths occurred (Table 1). The number and age-adjusted rates of fungal death per 100,000 population were similar in 2018 (n = 4,746) and 2019 (n = 4,833) (rate during both years: 1.2, 95% confidence interval [CI] = 1.2–1.3) and increased in 2020 (n = 5,922, rate: 1.5, 95% CI = 1.5–1.5) and 2021 (n = 7,199, rate: 1.8, 95% CI = 1.8–1.8). Of the 13,121 fungal deaths that occurred during 2020–2021, 2,868 (21.9%) were COVID-19–associated. For these 2,868 deaths, COVID-19 was the most frequent underlying cause of death (n = 2,596, 90.5%). COVID-19–associated fungal deaths (n = 2,868) comprised 0.3% of the total number of COVID-19 deaths (n = 840,817) during 2020–2021.
For all 2020–2021 fungal deaths (n = 13,121), the most commonly documented fungal pathogens were *Candida* (n = 3,208, 24.4%) and *Aspergillus* (n = 2,154, 16.4%); for 4,673 (35.6%) fungal deaths, the fungal pathogen was unspecified. Compared with non-COVID-19–associated fungal deaths (n = 10,253), COVID-19–associated fungal deaths (n = 2,868) more frequently involved *Candida* (n = 776 [27.1%] versus n = 2,432 [23.7%]) and *Aspergillus* (n = 668 [23.3%] versus n = 1,486 [14.5%]) and less frequently involved other specific fungal pathogens. During 2018–2021, the age-adjusted rate of death involving Mucorales spp. was <0.1 per 100,000 population each year; however, the number of fungal deaths involving Mucorales spp. increased from 134 in 2019 to 232 (47 COVID-19–associated, 185 non-COVID-19–associated) in 2021.

During 2018–2019, the average number of fungal deaths per month was 399 (median = 402, range = 351–492) (Figure 1). During the first US peak in COVID-19 deaths (April 2020), 423 fungal deaths occurred (47 COVID-19–associated, 376 non-COVID-19–associated). The monthly number of fungal deaths subsequently peaked during January 2021 (690 fungal deaths; 282 COVID-19 associated, 408 non-COVID-19–associated) and October 2021 (718 fungal deaths; 269 COVID-19–associated, 449 non-COVID-19–associated), coinciding with peaks in COVID-19 death counts.

Among the 13,121 persons who died from fungal infections during 2020–2021, the majority were aged ≥65 years (n = 7,102, 54.1%) and male (n = 7,828, 59.7%) (Table 2). For COVID-19–associated fungal deaths, age-adjusted death rates per 100,000 population were higher for persons who were AI/AN (1.3, 95% CI = 1.0–1.7), Hispanic (0.7, 95% CI = 0.7–0.8), and Black (0.6, 95% CI = 0.5–0.6), compared with White (0.2, 95% CI = 0.2–0.3) and Asian (0.3, 95% CI = 0.3–0.4) persons. Likewise, for non-COVID-19–associated fungal deaths, age-adjusted death rates were higher for persons who were AI/AN (3.0, 95% CI = 2.5–3.5), NHPI (2.4, 95% CI = 1.6–3.5), Black (1.9, 95% CI = 1.8–2.0), and Hispanic (1.5, 95% CI = 1.5–1.6) compared with White (1.1, 95% CI 1.1–1.2) and Asian (1.2, 95% CI = 1.1–1.3) persons. Crude fungal death rates per 100,000 population were higher among
residents of non-metropolitan areas (2.4, 95% CI 2.3–2.5) compared with residents of metropolitan areas (1.9, 95% CI = 1.9–2.0), a finding consistent across COVID-19–associated and non-COVID-19–associated fungal deaths.

Regarding geographic distribution, the observed age-adjusted rate of fungal deaths per 100,000 population were higher in the Mountain (2.1, 95% CI = 2.0–2.2) and Pacific (2.0, 95% CI = 1.9–2.1) US census divisions, and lower in the New England division (1.3, 95% CI = 1.1–1.4) (Figure 2). For COVID-19–associated fungal deaths, the observed rates were higher in the Mountain (0.5, 95% CI = 0.4–0.6) and West South Central (0.5, 95% CI = 0.4–0.5) divisions and lower in the New England (0.2, 95% CI = 0.2–0.3) division. The contribution of specific fungal pathogens to overall fungal death rates varied across US census divisions (Figure 3). Observed death rates from Coccidioides infections were higher in the Mountain (0.5, 95% CI = 0.5–0.6) and Pacific divisions (0.2, 95% CI = 0.2–0.3) and were <0.1 deaths per 100,000 population in all other US census divisions. Observed death rates from Aspergillus infections were approximately twice as high in the Pacific division (0.4, 95% CI = 0.4–0.5) compared with most other divisions.

DISCUSSION

Our analysis of US death certificate data found that >13,000 persons died from fungal infections during 2020–2021, representing an increase in the numbers and age-adjusted rates of death from fungal infections compared with previous years. This increase was primarily driven by COVID-19–associated fungal deaths, particularly those involving Aspergillus and Candida, and highlights the importance of considering fungal infections in patients with COVID-19. We also found striking racial/ethnic disparities and geographic differences in rates of death from fungal infections.

In our analysis, fungal death counts rose in tandem with COVID-19 surges during January and October 2021 but not during the first COVID-19 surge in April 2020. Recent analyses of testing practices have documented a precipitous decrease in testing for pathogens other than SARS-CoV-2 (the
virus that causes COVID-19) during April 2020, a finding that authors have attributed to strained healthcare resources during the early COVID-19 pandemic [17, 18]. We suspect that the absence of a peak in fungal deaths during April 2020 might reflect a lack of disease detection and reporting rather than a truly low number of COVID-19–associated fungal deaths. Conversely, the peaks in fungal deaths that occurred during January and October 2021 might reflect increased clinician awareness and testing for COVID-19–associated fungal infections, and possibly, the increased use of corticosteroids and tocilizumab (both known risk factors for invasive mold infections and candidiasis) [6] to treat patients with severe COVID-19.

Our finding that Candida and Aspergillus were the most commonly identified fungal pathogens causing death is consistent with previous literature describing fungal disease epidemiology both before and during the COVID-19 pandemic [6, 9, 12, 19]. In our analysis, a higher percentage of COVID-19–associated fungal deaths involved Candida and Aspergillus compared with non-COVID-19–associated fungal deaths, a finding that aligns with reports identifying COVID-19 as a risk factor for invasive aspergillosis and candidiasis [6, 12]. Although US data on the incidence of COVID-19–associated fungal infections are sparse, a multicenter study from Europe found that >10% of critically ill COVID-19 patients might develop invasive aspergillosis, with mortality rates exceeding 40% [12]. Limited reports also suggest that the incidence of invasive candidiasis might have increased during the COVID-19 pandemic [6, 20]. In contrast, research has not identified a clear link between the COVID-19 pandemic and the incidence of other types of fungal infections in the United States, although US cases of COVID-19–associated fungal infections with Pneumocystis, Cryptococcus, endemic fungi (i.e., Coccidioides, Histoplasma), and Mucorales spp. have all been reported [6, 10, 21-23].

Although we identified an increase in the number of deaths from Mucorales spp. during 2020–2021 compared with previous years, yearly rates of death for this pathogen remained low throughout the study period (<0.1 per 100,000 population). This finding is consistent with reports highlighting the rarity
of mucormycosis in the United States [4, 24, 25]. Nonetheless, previous reports suggest that
mucormycosis can cause severe illness, disfiguration, and death in COVID-19 patients, including among
those who lack severe immunocompromising conditions [10, 13].

Compared with the White and Asian populations, other groups had higher rates of fungal death,
particularly when examining fungal deaths associated with COVID-19. This finding is consistent with
previous literature describing the disproportionate burdens of both COVID-19 and fungal diseases on
certain communities of color [26]. Racial/ethnic disparities in the rates of infection and mortality from
COVID-19 are well documented and may stem from inequities in the social determinants of health; for
example, persons from certain racial/ethnic groups might be more likely to live in crowded settings, hold
jobs requiring in-person work, or have limited healthcare access [27, 28]. The impact of these inequities
might extend to fungal diseases, many of which are environmentally acquired and associated with
certain occupational exposures [29-31]. Other factors linked to inequities in the social determinants of
health, particularly differences in underlying conditions that increase fungal disease risk (e.g., diabetes)
and pre-COVID-19 health status, likely contributed to the observed racial/ethnic disparities in fungal
burden.

Fungal death rates varied widely among US census divisions, a finding largely accounted for by
differences in rates of death from Coccidioides and Aspergillus infections. Coccidioides is primarily
demic to the southwestern United States; that this pathogen contributed so markedly to the fungal
death rates in the Mountain and Pacific divisions underscores the threat it poses to public health in the
region [32]. To our knowledge, the finding that death rates from Aspergillus were twice as high in the
Pacific division compared with other divisions has not previously been documented, although research
suggests that airborne Aspergillus spore counts and rates of invasive aspergillosis might vary depending
on factors such as temperature, precipitation, geography, and season [33]. The geographic distribution of
aspergillosis has not been well described, in part because aspergillosis is only reportable in one US state
Greater public health surveillance for fungal infections, involving geographically and
demographically diverse populations, might provide critical information to guide the prevention,
diagnosis, and treatment of fungal diseases.

Because US census divisions have differing racial/ethnic compositions and because fungal death
rates varied substantially by both US census division and race/ethnicity, we assessed potential
confounding or interactions between race/ethnicity and census division by examining division-stratified
racial/ethnic fungal death rates and race/ethnicity-stratified division fungal death rates. A complete
analysis of these stratified death rates was not possible because of NVSS privacy restrictions on small
data cells involving geographically stratified data. However, we found that racial/ethnic disparities
generally persisted within each US census division and that rates of fungal deaths generally differed by
race/ethnicity when stratified by census division (data not shown). Further research may help to describe
the intersection of demographic and geographic factors associated with severe fungal diseases.

Our findings have several notable limitations. First, provisional mortality data from 2021 are
incomplete and subject to change, particularly during recent months, as delayed reports might later
increase death counts. Our use of broad single race categories limited the level of detail with which we
could assess racial/ethnic disparities, particularly among multiracial persons. Another limitation was that
we could not assess underlying medical conditions among patients with COVID-19–associated fungal
deaths; this is because the CDC-WONDER platform does not allow for the tabulation of more than two
sets of conditions in combination. Further, data based on ICD-10 codes for fungal infections,
particularly those for mold infections such as invasive aspergillosis, are subject to imprecision in
reporting and underreporting [35]. In our analysis, more than one-third of deaths involved an unspecified
fungal pathogen, limiting our ability to precisely describe each fungal pathogen’s contribution to overall
fungal mortality. Also, our analysis likely underestimates the impact of fungal diseases during the
COVID-19 pandemic. Current fungal diagnostic tests generally lack sensitivity and might not be widely
available or utilized if healthcare providers do not suspect a fungal infection [36, 37]. Deaths from invasive mold infections including aspergillosis might be particularly undercounted because this diagnosis is frequently missed. Studies of autopsies, a procedure performed for <5% of COVID-19 decedents during 2020–2021 [8], have identified mold infections as one of the most commonly missed diseases among ICU and hematologic malignancy patients [38, 39]. Finally, in focusing only on deaths from fungal infections, our analysis did not address the considerable long-term morbidity faced by certain survivors of severe fungal infection [40].

Despite its limitations, our analysis demonstrates the substantial burden of fungal infections in the United States and highlights an increase in fungal deaths during the first two years of COVID-19 pandemic. These data might help increase clinician awareness and support public health planning, with the ultimate goals of decreasing morbidity and mortality from fungal infections. Detailed public health surveillance for fungal infections, involving geographically and demographically diverse patient populations, might help better characterize disease epidemiology and guide ongoing efforts to prevent fungal infections among disproportionately affected populations.

NOTES

Acknowledgments: Nancy Chow and Zeyu Li. We are grateful for the efforts of vital statistics jurisdictions in their continued collaboration with the National Center for Health Statistics and provision of data during the COVID-19 pandemic.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq).

Funding: No specific funding was used to complete this work.

Conflicts of interest: The authors report no potential conflicts of interest.
References:

1. Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of Direct Healthcare Costs of Fungal Diseases in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019; 68(11): 1791-7.

2. Rayens E, Norris KA, Cordero JF. Mortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999–2018. Clinical Infectious Diseases 2021; 74(2): 309-18.

3. Neofytos D, Treadway S, Ostrander D, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transplant infectious disease : an official journal of the Transplantation Society 2013; 15(3): 233-42.

4. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012; 54 Suppl 1(Suppl 1): S16-22.

5. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2015; 62(4): e1-e50.

6. Baddley JW, Thompson GR, III, Chen SC-A, et al. Coronavirus Disease 2019–Associated Invasive Fungal Infection. Open forum infectious diseases 2021; 8(12).

7. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. The New England journal of medicine 2020; 382(10): 929-36.

8. Centers for Disease Control and Prevention, National Center for Health Statistics. Provisional Multiple Cause of Death on CDC WONDER Online Database, released 2021. Data are from the final Multiple Cause of Death Files, 2018-2020, and from provisional data for years 2020-2021, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics
Cooperative Program. Accessed at http://wonder.cdc.gov/mcd-icd10-provisional.html on Mar 9, 2022 7:39:36 AM.

9. Seagle EE, Jackson BR, Lockhart SR, et al. The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic. Clinical Infectious Diseases 2021.

10. Dulski TM, DeLong M, Garner K, et al. Notes from the Field: COVID-19-Associated Mucormycosis - Arkansas, July-September 2021. MMWR Morbidity and mortality weekly report 2021; 70(50): 1750-1.

11. Narayanan S, Chua JV, Baddley JW. COVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease. Clinical Infectious Diseases 2021.

12. Janssen NAF, Nyga R, Vanderbeke L, et al. Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis(1). Emerging infectious diseases 2021; 27(11): 2892-8.

13. Mejia-Chew C, O'Halloran JA, Olsen MA, et al. Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. The Lancet Infectious Diseases 2019; 19(12): 1336-44.

14. Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. JAMA 2021; 325(18): 1829-30.

15. Centers for Disease Control and Prevention. Instructions for Classifying the Multiple Causes of Death, 2021. National Vital Statistics System. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2021; https://www.cdc.gov/nchs/nvss/manuals/2a-sectioni-2021.htm Accessed: May 14, 2022.

16. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes 2001; (20): 1-10.

17. Pinto CN, Niles JK, Kaufman HW, et al. Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the U.S. Am J Prev Med 2021; 61(3): 386-93.
18. Kaufman HW, Bull-Otterson L, Meyer WA, 3rd, et al. Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. Am J Prev Med 2021; 61(3): 369-76.

19. Rayens E, Norris KA. Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018. Open forum infectious diseases 2022; 9(1).

20. Nucci M, Barreiros G, Guimarães LF, Deriquehem VAS, Castiñeiras AC, Nouér SA. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses 2021; 64(2): 152-6.

21. Shah AS, Heidari A, Civelli VF, et al. The Coincidence of 2 Epidemics, Coccidioidomycosis and SARS-CoV-2: A Case Report. J Investig Med High Impact Case Rep 2020; 8: 2324709620930540.

22. Menon AA, Berg DD, Brea EJ, et al. A Case of COVID-19 and Pneumocystis jirovecii Coinfection. American journal of respiratory and critical care medicine 2020; 202(1): 136-8.

23. Heller HM, Gonzalez RG, Edlow BL, Ard KL, Gogakos T. Case 40-2020: A 24-Year-Old Man with Headache and Covid-19. The New England journal of medicine 2020; 383(26): 2572-80.

24. Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 2022.

25. Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses 2021.

26. Gold JAW, Rossen LM, Ahmad FB, et al. Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 — United States, May–August 2020. MMWR Morbidity and mortality weekly report 2020; 69(42): 1517-21.

27. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. JAMA 2020; 323(24): 2466-7.
28. Bui DP, McCaffrey K, Friedrichs M, et al. Racial and Ethnic Disparities Among COVID-19 Cases in Workplace Outbreaks by Industry Sector — Utah, March 6–June 5, 2020. MMWR Morbidity and mortality weekly report 2020; 69(33): 1133-8.

29. de Perio MA, Benedict K, Williams SL, et al. Occupational Histoplasmosis: Epidemiology and Prevention Measures. Journal of fungi (Basel, Switzerland) 2021; 7(7).

30. Das R, McNary J, Fitzsimmons K, et al. Occupational coccidioidomycosis in California: outbreak investigation, respirator recommendations, and surveillance findings. J Occup Environ Med 2012; 54(5): 564-71.

31. Choptiany M, Wiebe L, Limerick B, et al. Risk factors for acquisition of endemic blastomycosis. Can J Infect Dis Med Microbiol 2009; 20(4): 117-21.

32. Lockhart SR, Toda M, Benedict K, Caceres DH, Litvintseva AP. Endemic and Other Dimorphic Mycoses in The Americas. Journal of fungi (Basel, Switzerland) 2021; 7(2).

33. Panackal AA, Li H, Kontoyiannis DP, et al. Geoclimatic Influences on Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases 2010; 50(12): 1588-97.

34. Centers for Disease Control and Prevention. Reportable Fungal Diseases by State. Atlanta, GA: US Department of Health and Human Services, CDC. https://www.cdc.gov/fungal/fungal-disease-reporting-table.html Accessed: January 28, 2022.

35. Gold JAW, Revis A, Thomas S, et al. Clinical Characteristics, Healthcare Utilization, and Outcomes among Patients in a Pilot Surveillance System for Invasive Mold Disease—Georgia, United States, 2017–2019. Open forum infectious diseases 2022.

36. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013; 56(9): 1284-92.
37. Lass-Flörl C. Current Challenges in the Diagnosis of Fungal Infections. Methods Mol Biol 2017; 1508: 3-15.

38. Tejerina EE, Abril E, Padilla R, et al. Invasive aspergillosis in critically ill patients: An autopsy study. Mycoses 2019; 62(8): 673-9.

39. Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 2013; 56(6): 638-45.

40. Thompson GR, 3rd. Pulmonary coccidioidomycosis. Semin Respir Crit Care Med 2011; 32(6): 754-63.
Table 1. Deaths from fungal infections and COVID-19 — National Vital Statistics System Multiple Cause of Death Database, United States, 2018–2021

| Fungal pathogen | 2018 No. (%) | 2018 Rate, 95% CI | 2019 No. (%) | 2019 Rate, 95% CI | All No. (%) | All Rate, 95% CI | COVID-19-associated No. (%) | COVID-19-associated Rate, 95% CI |
|----------------|-------------|-------------------|-------------|-------------------|------------|----------------|--------------------------|-------------------------------|
| Aspergillus     | 795 (16.8)  | 0.2, 0.1–0.2      | 723 (15.0)  | 0.2, 0.2–0.2      | 918 (21.3) | 0.2, 0.2–0.3   | 170 (18.9) 0.0, 0.0–0.0   | (17.2) (0.3, 0.0–0.3) (25.3) 0.1–0.1 |
| Candida         | 1,010 (0.3) | 0.3, 0.0–0.3      | 1,171 (0.3) | 0.3, 0.3–0.3      | 1,439 (0.3) | 0.3, 0.3–0.4   | 281 (0.1) 0.1, 0.0–0.1    | (1.76) (0.4, 0.0–0.4) 495 0.1 |
| Coccidioides    | 253 (5.3)   | 0.1, 0.0–0.1      | 192 (0.0)   | 0.0, 0.0–0.0      | 319 (0.1)  | 0.1, 0.1–0.1   | 33 (0.0) 0.0, 0.0–0.0     | 359 0.1, 0.1–0.1 |
| Cryptococcus    | 146 (6.1)   | 0.1, 0.0–0.1      | 133 (0.0)   | 0.0, 0.0–0.0      | 130 (0.0)  | 0.0, 0.0–0.0   | 6 (0.0) 0.0, 0.0–0.0      | 199 0.0, 0.0–0.1 |
| Histoplasma     | 151 (3.1)   | 0.0, 0.0–0.0      | 134 (0.0)   | 0.0, 0.0–0.0      | 169 (0.0)  | 0.0, 0.0–0.0   | 17 (0.0) 0.0, 0.0–0.0     | 232 0.0, 0.0–0.1 |
| Mucorales spp.  | 371 (3.2)   | 0.0, 0.0–0.0      | 436 (0.1)   | 0.1, 0.1–0.1      | 381 (0.1)  | 0.1, 0.1–0.1   | 13 (0.0) 0.0, 0.0–0.0     | 449 0.1, 0.1–0.1 |
| Pneumocystis    | 116 (7.8)   | 0.0, 0.0–0.0      | 118 (0.0)   | 0.0, 0.0–0.0      | 131 (0.0)  | 0.0, 0.0–0.0   | 3 (0.0) 0.0, 0.0–0.0      | 131 0.0, 0.0–0.0 |
| Other specified pathogens | 2,494 (2.4) | 0.0, 0.0–0.0 | 2,494 (2.4) | 0.0, 0.0–0.0 | 2,494 (2.4) | 0.0, 0.0–0.0 | 2,494 (2.4) | 0.0, 0.0–0.0 |
| Unspecified     | 1,649 (0.4) | 0.4, 0.3–0.5      | 1,623 (0.4) | 0.4, 0.4–0.5      | 2,135 (0.5) | 0.5, 0.5–0.6   | 362 (0.1) 0.1, 0.0–0.1    | 2,538 0.7, 0.6–0.7 |
| All             | 4,746 (1.2) | 1.2, 1.1–1.3      | 4,833 (1.2) | 1.2, 1.1–1.3      | 5,922 (1.5) | 1.5, 1.4–1.6   | 901 (0.2) 0.2, 0.1–0.2    | (1.799) (1.8, 1.7–1.8) |

Abbreviation: ICD-10 = International Classification of Diseases, Tenth Revision; CI = confidence interval
Data for 2021 are provisional and were last updated February 6, 2022. Death certificates could list more than one fungal ICD-10-CM code; this occurred on <1% of death certificates listing a fungal pathogen. Fungal deaths were defined as deaths where a fungal infection was listed as a contributing or underlying cause of death. COVID-19–associated deaths were defined as deaths where COVID-19 was listed as a contributing or underlying cause of death. The method for calculating the 95% confidence intervals is available online (https://wonder.cdc.gov/wonder/help/mcd-provisional.html#Confidence-Intervals). Age-adjusted death rates were calculated by the direct method using the 2000 U.S. standard population (https://wonder.cdc.gov/wonder/help/mcd-provisional.html#2000%20Standard%20Population). Rates are not shown for groups where the death count was less than 20 (indicated by the symbol “—”). Rates were rounded to one decimal point; therefore, rates of “0.0” might not represent true zeros.
Table 2. Demographic characteristics of persons who died from fungal infections and COVID-19 — National Vital Statistics System Multiple Cause of Death Database, United States, 2020–2021

| Characteristic       | All fungal deaths | COVID-19–associated | Non-COVID-19–associated |
|----------------------|-------------------|----------------------|-------------------------|
|                      | No.   | %     | rate (95% CI)       | No.   | %     | rate (95% CI)       | No.   | %     | rate (95% CI)       |
| Overall              | 13,121 | 100.0 | 1.6 (1.6–1.7)       | 2,868 | 100.0 | 0.4 (0.4–0.4)       | 10,253 | 100.0 | 1.3 (1.3–1.3)       |
| Age group, yrs       |        |       |                      |        |       |                      |        |       |                      |
| <1                   | 70     | 0.5   | 0.9 (0.7–1.2)       | 1      | 0.0   | —                   | 69     | 0.7   | 0.9 (0.7–1.2)       |
| 1–4                  | 39     | 0.3   | 0.1 (0.1–0.2)       | 1      | 0.0   | —                   | 38     | 0.4   | 0.1 (0.1–0.2)       |
| 5–14                 | 97     | 0.7   | 0.1 (0.1–0.1)       | 7      | 0.2   | —                   | 90     | 0.9   | 0.1 (0.1–0.1)       |
| 15–24                | 193    | 1.5   | 0.2 (0.2–0.3)       | 20     | 0.7   | 0.0 (0.0–0.0)       | 173    | 1.7   | 0.2 (0.2–0.2)       |
| 25–34                | 464    | 3.5   | 0.5 (0.5–0.5)       | 58     | 2.0   | 0.1 (0.0–0.1)       | 406    | 4.0   | 0.4 (0.4–0.5)       |
| 35–44                | 766    | 5.8   | 0.9 (0.8–1.0)       | 135    | 4.7   | 0.2 (0.1–0.2)       | 631    | 6.2   | 0.7 (0.7–0.8)       |
| 45–54                | 1,476  | 11.2  | 1.8 (1.7–1.9)       | 364    | 12.7  | 0.5 (0.4–0.5)       | 1,112  | 10.8  | 1.4 (1.3–1.5)       |
| 55–64                | 2,914  | 22.2  | 3.4 (3.3–3.6)       | 764    | 26.6  | 0.9 (0.8–1.0)       | 2,150  | 21.0  | 2.5 (2.4–2.6)       |
| 65–74                | 3,742  | 28.5  | 5.7 (5.6–5.9)       | 851    | 29.7  | 1.3 (1.2–1.4)       | 2,891  | 28.2  | 4.4 (4.3–4.6)       |
| 75–84                | 2,454  | 18.7  | 7.6 (7.2–7.8)       | 529    | 18.4  | 1.6 (1.5–1.7)       | 1,925  | 18.8  | 5.9 (5.6–6.1)       |
| ≥85                  | 906    | 6.9   | 6.8 (6.4–7.2)       | 138    | 4.8   | 1.0 (0.9–1.2)       | 768    | 7.5   | 5.8 (5.4–6.2)       |
| Male sex             | 7,828  | 59.7  | 2.1 (2.1–2.2)       | 1,800  | 62.8  | 0.5 (0.4–0.5)       | 6,028  | 58.8  | 1.6 (1.6–1.7)       |
| Race/ethnicity       |        |       |                      |        |       |                      |        |       |                      |
| White, NH            | 7,837  | 59.7  | 1.4 (1.4–1.4)       | 1,440  | 50.2  | 0.2 (0.2–0.3)       | 6,397  | 62.4  | 1.1 (1.1–1.2)       |
| Hispanic or Latino   | 2,195  | 16.7  | 2.3 (2.2–2.4)       | 719    | 25.1  | 0.7 (0.7–0.8)       | 1,476  | 14.4  | 1.5 (1.5–1.6)       |
| Black, NH            | 2,088  | 15.9  | 2.5 (2.3–2.6)       | 469    | 16.4  | 0.6 (0.5–0.6)       | 1,619  | 15.8  | 1.9 (1.8–2.0)       |
| Asian, NH            | 621    | 4.7   | 1.5 (1.4–1.6)       | 132    | 4.6   | 0.3 (0.3–0.4)       | 489    | 4.8   | 1.2 (1.1–1.3)       |
| American Indian or   | 215    | 1.6   | 4.3 (3.7–4.9)       | 67     | 2.3   | 1.3 (1.0–1.7)       | 148    | 1.4   | 3.0 (2.5–3.5)       |
| Alaska Native, NH    |        |       |                      |        |       |                      |        |       |                      |
| Race/Ethnicity                  | Age-adjusted Death Rate (per 100,000) | Crude Death Rate (per 100,000) | Death Count | 95% CI         | NH Death Count | 95% CI         |
|--------------------------------|--------------------------------------|-------------------------------|-------------|---------------|----------------|---------------|
| Native Hawaiian or other Pacific, NH | 43 0.3 3.8 (2.7–5.1)                  | 17 —                           | 26 0.3      | 2.4 (1.6–3.5) |                |               |
| Multiracial, NH               | 85 0.6 1.0 (0.8–1.2)                  | 17 —                           | 68 0.7      | 0.8 (0.6–1.0) |                |               |
| Unknown                       | 37 —                                  | 7 —                            | 30 —        |               |                |               |

**Urban-rural 2013 classification of residence**

| Urban-rural Classification | Death Count | Age-adjusted Death Rate (per 100,000) | Crude Death Rate (per 100,000) | Death Count | 95% CI         | NH Death Count | 95% CI         |
|----------------------------|-------------|--------------------------------------|-------------------------------|-------------|---------------|----------------|---------------|
| Metropolitan               | 10,948      | 83.4 1.9 (1.9–2.0)                   | 2,351 82.0 0.4 (0.4–0.4)       | 8,597       | 83.8 1.5 (1.5–1.5) |                |               |
| Large central metro        | 4,186       | 31.9 2.1 (2.0–2.1)                   | 933 32.5 0.5 (0.4–0.5)         | 3,253       | 31.7 1.6 (1.6–1.7) |                |               |
| Large fringe metro         | 2,764       | 21.1 1.7 (1.6–1.7)                   | 567 19.8 0.3 (0.3–0.4)         | 2,197       | 21.4 1.3 (1.3–1.4) |                |               |
| Medium metro               | 2,772       | 21.1 2.0 (1.9–2.1)                   | 553 19.3 0.4 (0.4–0.4)         | 2,219       | 21.6 1.6 (1.5–1.7) |                |               |
| Small metro                | 1,226       | 9.3 2.0 (1.9–2.2)                    | 298 10.4 0.5 (0.4–0.6)         | 928         | 9.1 1.5 (1.4–1.6) |                |               |
| Non-metropolitan           | 2,173       | 16.6 2.4 (2.3–2.5)                   | 517 18.0 0.6 (0.5–0.6)         | 1,656       | 16.2 1.8 (1.7–1.9) |                |               |
| Micropolitan               | 1,211       | 9.2 2.2 (2.1–2.3)                    | 287 10.0 0.5 (0.5–0.6)         | 924         | 9.0 1.7 (1.6–1.8) |                |               |
| Non-core                   | 962         | 7.3 2.6 (2.4–2.7)                    | 230 8.0 0.6 (0.5–0.7)          | 732         | 7.1 2.0 (1.8–2.1) |                |               |

**Abbreviation:** NH = non-Hispanic/non-Latino

*Data for 2021 are provisional and were last updated February 6, 2022. COVID-19–associated fungal deaths (n = 2,868) comprised 0.3% of the total number of COVID-19 deaths (n = 840,817) during 2020–2021.*

*For these 2,868 deaths, COVID-19 was the most frequent underlying cause of death (n = 2,596, 90.5%)*

*Age-adjusted rates are shown for sex and race/ethnicity; crude rates are shown for age groups and urban-rural 2013 classification of residence. Rates are not shown for conditions where the death count was less than 20, and rates were not available for persons with “unknown” race/ethnicity. These suppressed rates are indicated by the symbol “—”. The method for calculating the 95% confidence intervals is available online: https://wonder.cdc.gov/wonder/help/mcd-provisional.html#Confidence-Intervals. Age-adjusted death rates were calculated using the 2000 U.S. standard population (https://wonder.cdc.gov/wonder/help/mcd-provisional.html#2000%20Standard%20Population).*

*https://www.cdc.gov/nchs/data_access/urban_rural.htm*
FIGURE LEGENDS

Figure 1. Monthly number of deaths from fungal infections and COVID-19 — National Vital Statistics System, United States, 2018–2021a

aData for 2021 are provisional and were last updated February 6, 2022.

Figure 2. Age-adjusted rates of death (per 100,000 population) for all fungal deaths (A) and COVID-19–associated fungal deaths (B) by US census division of residence,a National Vital Statistics System — United States, 2020–2021b

bThe United States Census Bureau defines nine census divisions: New England (CT, MA, ME, NH, RI, and VT), Middle Atlantic (NJ, NY, and PA), East North Central (IL, IN, MI, OH, and WI), West North Central (IA, KS, MN, MO, ND, NE, and SD), South Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, and WV), East South Central (AL, KY, MS, and TN), West South Central (AR, LA, OK, and TX), Mountain (AZ, CO, ID, MT, NM, NV, UT, and WY), and Pacific (AK, CA, HI, OR, and WA) divisions.

bData for 2021 are provisional and were last updated February 6, 2022. Error bars represent 95% confidence intervals.

Figure 3. Age-adjusted rates of death from fungal infections, by US census division of residencea — National Vital Statistics System, United States, 2020–2021b

bThe United States Census Bureau defines nine census divisions: New England (CT, MA, ME, NH, RI, and VT), Middle Atlantic (NJ, NY, and PA), East North Central (IL, IN, MI, OH, and WI), West North Central (IA, KS, MN, MO, ND, NE, and SD), South Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, and WV), East South Central (AL, KY, MS, and TN), West South Central (AR, LA, OK, and TX), Mountain (AZ, CO, ID, MT, NM, NV, UT, and WY), and Pacific (AK, CA, HI, OR, and WA) divisions.

bData for 2021 are provisional and were last updated February 6, 2022. Rates are not shown for conditions where the death count was less than 20.
Figure 1
178x130 mm (.29 x DPI)
